Adjuvanted trivalent influenza virus vaccine (aTIV)

BIOLOGICAL2 trials

Sponsors

Novartis, Novartis Vaccines

Conditions

Human InfluenzaPandemic Influenza Disease

Phase 2

Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects

CompletedNCT01651104

Novartis VaccinesHuman Influenza

Start: 2012-07-31End: 2012-08-31Updated: 2014-04-21

Phase 3

Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects

CompletedNCT00841763

NovartisPandemic Influenza Disease

Start: 2008-10-31End: 2009-11-30Updated: 2021-04-23